𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Mutational status of EGFR and KIT in thymoma and thymic carcinoma

✍ Scribed by Yoh, Kiyotaka; Nishiwaki, Yutaka; Ishii, Genichiro; Goto, Koichi; Kubota, Kaoru; Ohmatsu, Hironobu; Niho, Seiji; Nagai, Kanji; Saijo, Nagahiro

Book ID
119319910
Publisher
Elsevier Science
Year
2008
Tongue
English
Weight
301 KB
Volume
62
Category
Article
ISSN
0169-5002

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

COX-2 upregulation in thymomas and thymi
COX-2 upregulation in thymomas and thymic carcinomas
✍ Ralf J. Rieker; Stefan Joos; Gunhild Mechtersheimer; Hendrik Blaeker; Philipp A. πŸ“‚ Article πŸ“… 2006 πŸ› John Wiley and Sons 🌐 French βš– 289 KB

## Abstract The treatment of advanced stage thymomas and thymic carcinomas is a multimodal therapy. New therapeutic targets are currently under investigation, including the epidermal growth factor receptor (EGFR) as well as KIT. A number of studies have shown protumorigenic potential of Cyclooxygen